• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨肉瘤患者癌症特异性生存预测的竞争风险模型的建立与验证:一项基于人群的研究

Establishment and validation of a competitive risk model for predicting cancer-specific survival in patients with osteosarcoma: a population-based study.

作者信息

Wu Xin, Wang Jinkui, He Dawei

机构信息

Department of Urology, Children's Hospital of Chongqing Medical University, 2 ZhongShan Rd, Chongqing, 400013, Chongqing, China.

Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China.

出版信息

J Cancer Res Clin Oncol. 2023 Nov;149(17):15383-15394. doi: 10.1007/s00432-023-05320-x. Epub 2023 Aug 28.

DOI:10.1007/s00432-023-05320-x
PMID:37639006
Abstract

BACKGROUND

Osteosarcoma is the most common primary bone tumor with a poor prognosis. The aim of this study was to establish a competitive risk model nomogram to predict cancer-specific survival in patients with osteosarcoma.

METHODS

Patient data was obtained from the Surveillance, Epidemiology, and End Results database in the United States. A sub-distribution proportional hazards model was used to analyze independent risk factors affecting cancer-specific mortality (CSM) in osteosarcoma patients. Based on these risk factors, a competitive risk model was constructed to predict 1-year, 3-year, and 5-year cancer-specific survival (CSS) in osteosarcoma patients. The reliability and accuracy of the nomogram were evaluated using the concordance index (C-index), the area under the receiver operating characteristic curve (AUC), and calibration curves.

RESULTS

A total of 2900 osteosarcoma patients were included. The analysis showed that age, primary tumor site, M stage, surgery, chemotherapy, and median household income were independent risk factors influencing CSM in patients. The competitive risk model was constructed to predict CSS in osteosarcoma patients. In the training and validation sets, the C-index of the model was 0.756 (95% CI 0.725-0.787) and 0.737 (95% CI 0.717-0.757), respectively, and the AUC was greater than 0.7 for both. The calibration curves also demonstrated a high consistency between the predicted survival rates and the actual survival rates, confirming the accuracy and reliability of the model.

CONCLUSION

We established a competitive risk model to predict 1-year, 3-year, and 5-year CSS in osteosarcoma patients. The model demonstrated good predictive performance and can assist clinicians and patients in making clinical decisions and formulating follow-up strategies.

摘要

背景

骨肉瘤是最常见的原发性骨肿瘤,预后较差。本研究的目的是建立一个竞争风险模型列线图,以预测骨肉瘤患者的癌症特异性生存情况。

方法

患者数据来自美国监测、流行病学和最终结果数据库。采用亚分布比例风险模型分析影响骨肉瘤患者癌症特异性死亡率(CSM)的独立危险因素。基于这些危险因素,构建竞争风险模型以预测骨肉瘤患者1年、3年和5年的癌症特异性生存率(CSS)。使用一致性指数(C指数)、受试者操作特征曲线下面积(AUC)和校准曲线评估列线图的可靠性和准确性。

结果

共纳入2900例骨肉瘤患者。分析表明,年龄、原发肿瘤部位、M分期、手术、化疗和家庭收入中位数是影响患者CSM的独立危险因素。构建竞争风险模型以预测骨肉瘤患者的CSS。在训练集和验证集中,模型的C指数分别为0.756(95%CI 0.725-0.787)和0.737(95%CI 0.717-0.757),两者的AUC均大于0.7。校准曲线也显示预测生存率与实际生存率之间具有高度一致性,证实了模型的准确性和可靠性。

结论

我们建立了一个竞争风险模型来预测骨肉瘤患者1年、3年和5年的CSS。该模型具有良好的预测性能,可协助临床医生和患者做出临床决策并制定随访策略。

相似文献

1
Establishment and validation of a competitive risk model for predicting cancer-specific survival in patients with osteosarcoma: a population-based study.骨肉瘤患者癌症特异性生存预测的竞争风险模型的建立与验证:一项基于人群的研究
J Cancer Res Clin Oncol. 2023 Nov;149(17):15383-15394. doi: 10.1007/s00432-023-05320-x. Epub 2023 Aug 28.
2
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
3
Establishment of a prognostic nomogram and risk stratification system for patients with distant-metastatic hepatocellular carcinoma: A population-based study.远处转移肝细胞癌患者预后列线图及风险分层系统的建立:一项基于人群的研究。
Medicine (Baltimore). 2025 Jun 13;104(24):e42834. doi: 10.1097/MD.0000000000042834.
4
Competing risk and random survival forest models for predicting survival in post-resection elderly stage I-III colorectal cancer patients.用于预测I-III期老年结直肠癌患者术后生存情况的竞争风险和随机生存森林模型
Sci Rep. 2025 Jul 7;15(1):24269. doi: 10.1038/s41598-025-05824-1.
5
Development and validation of nomograms for predicting survival of locally advanced rectosigmoid junction cancer patients: a SEER database analysis.预测局部晚期直肠乙状结肠交界处癌患者生存的列线图的开发与验证:一项监测、流行病学和最终结果(SEER)数据库分析
Transl Cancer Res. 2025 May 30;14(5):2808-2821. doi: 10.21037/tcr-24-1810. Epub 2025 May 27.
6
Individualized Prediction of Overall Survival Time for Patients with Primary Intramedullary Spinal Cord Astrocytoma: A Population-Based Study.原发性脊髓髓内星形细胞瘤患者总生存时间的个体化预测:一项基于人群的研究
World Neurosurg. 2025 Jan;193:1106-1116. doi: 10.1016/j.wneu.2024.10.092. Epub 2024 Nov 21.
7
Two web-based dynamically interactive nomograms and risk stratification systems for predicting survival outcomes and guiding treatment in non-metastatic nasopharyngeal carcinoma.用于预测非转移性鼻咽癌生存结局并指导治疗的两个基于网络的动态交互式列线图和风险分层系统。
J Cancer Res Clin Oncol. 2023 Nov;149(17):15969-15987. doi: 10.1007/s00432-023-05363-0. Epub 2023 Sep 8.
8
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
9
Dynamic nomogram for predicting the overall survival and cancer-specific survival of patients with gastrointestinal neuroendocrine tumor: a SEER-based retrospective cohort study and external validation.预测胃肠道神经内分泌肿瘤患者总生存期和癌症特异性生存期的动态列线图:一项基于监测、流行病学和最终结果(SEER)数据库的回顾性队列研究及外部验证
Front Oncol. 2025 Jun 4;15:1594591. doi: 10.3389/fonc.2025.1594591. eCollection 2025.
10
Prediction of death probability in adenocarcinoma of the transverse colon: competing-risk nomograms based on 21,469 patients.横结肠癌死亡概率的预测:基于21469例患者的竞争风险列线图
J Cancer Res Clin Oncol. 2023 Sep;149(12):10435-10452. doi: 10.1007/s00432-023-04913-w. Epub 2023 Jun 6.

引用本文的文献

1
Development and validation of the competing risk nomogram and risk classification system for predicting cancer-specific mortality in patients with cervical adenosquamous carcinoma treated via radical hysterectomy.用于预测接受根治性子宫切除术治疗的宫颈腺鳞癌患者癌症特异性死亡率的竞争风险列线图和风险分类系统的开发与验证。
Biomol Biomed. 2025 Apr 3;25(5):1099-1110. doi: 10.17305/bb.2024.11217.
2
UBE2L3 Suppresses Oxidative Stress-regulated Necroptosis to Accelerate Osteosarcoma Progression.UBE2L3抑制氧化应激调节的坏死性凋亡以加速骨肉瘤进展。
Recent Pat Anticancer Drug Discov. 2025;20(1):102-112. doi: 10.2174/0115748928297557240212112531.

本文引用的文献

1
Advancement of prognostic models in breast cancer: a narrative review.乳腺癌预后模型的进展:一项叙述性综述。
Gland Surg. 2021 Sep;10(9):2815-2831. doi: 10.21037/gs-21-441.
2
Nomogram for predicting the overall survival of patients with inflammatory breast cancer: A SEER-based study.基于 SEER 数据库的炎性乳腺癌患者总生存预测列线图研究。
Breast. 2019 Oct;47:56-61. doi: 10.1016/j.breast.2019.05.015. Epub 2019 Jul 17.
3
Prognostic nomograms for predicting overall and cancer-specific survival of high-grade osteosarcoma patients.
用于预测高级别骨肉瘤患者总生存和癌症特异性生存的预后列线图。
J Bone Oncol. 2018 Oct 4;13:106-113. doi: 10.1016/j.jbo.2018.09.012. eCollection 2018 Nov.
4
Nomogram application to predict overall and cancer-specific survival in osteosarcoma.用于预测骨肉瘤总生存率和癌症特异性生存率的列线图应用
Cancer Manag Res. 2018 Nov 8;10:5439-5450. doi: 10.2147/CMAR.S177945. eCollection 2018.
5
Development and Validation of Nomograms Predicting Overall and Cancer-Specific Survival of Spinal Chondrosarcoma Patients.列线图预测脊柱软骨肉瘤患者总生存和癌症特异性生存的建立与验证。
Spine (Phila Pa 1976). 2018 Nov 1;43(21):E1281-E1289. doi: 10.1097/BRS.0000000000002688.
6
Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study.氟代脱氧葡萄糖正电子发射断层扫描代谢和容量参数对儿童骨肉瘤的预后价值:一项假说生成研究。
Radiology. 2018 Apr;287(1):303-312. doi: 10.1148/radiol.2017162758. Epub 2018 Jan 19.
7
Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.青少年及青年肿瘤学,版本 2.2018,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2018 Jan;16(1):66-97. doi: 10.6004/jnccn.2018.0001.
8
Current and future therapeutic approaches for osteosarcoma.骨肉瘤的当前及未来治疗方法
Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50. doi: 10.1080/14737140.2018.1413939. Epub 2017 Dec 14.
9
Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival.头颈部骨肉瘤的化疗:辅助化疗可提高总生存率。
Oral Oncol. 2017 Oct;73:124-131. doi: 10.1016/j.oraloncology.2017.08.017. Epub 2017 Sep 1.
10
CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial.CD163阳性肿瘤相关巨噬细胞和CD8阳性细胞毒性淋巴细胞是骨肉瘤患者治疗分层的有力诊断标志物:对法国OS2006三期试验活检样本的免疫组织化学分析
Oncoimmunology. 2017 Aug 24;6(9):e1331193. doi: 10.1080/2162402X.2017.1331193. eCollection 2017.